SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma jumps on planning to launch 50-60 new products in US in FY21

23 Jun 2020 Evaluate
Aurobindo Pharma is currently trading at Rs. 810.00, up by 23.60 points or 3.00% from its previous closing of Rs. 786.40 on the BSE.

The scrip opened at Rs. 787.00 and has touched a high and low of Rs. 816.50 and Rs. 787.00 respectively. So far 115699 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 816.50 on 23-Jun-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 816.50 and Rs. 770.00 respectively. The current market cap of the company is Rs. 47507.90 crore.

The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 34.82% and 13.16% respectively.

Aurobindo Pharma is planning to launch 50 to 60 new products in US in FY21. The company has received final approval for six ANDAs (Abbreviated New Drug Application) and launched four products in the fourth quarter of last fiscal. For the full year, it has received approval for 22 ANDAs and launched 34 products across oral, injectable and OTC segments.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1405.35 14.20 (1.02%)
22-Apr-2026 12:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1663.20
Dr. Reddys Lab 1225.70
Cipla 1236.25
Zydus Lifesciences 928.85
Lupin 2314.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×